Highlight
- High-dose levothyroxine (L-T4) therapy safely raises thyroid hormone levels in adult RTHα patients without adverse clinical effects over three years.
- Patients report improved quality of life despite biochemical profiles showing supraphysiological free thyroxine (FT4), free triiodothyronine (FT3), and reverse T3 (rT3) levels with suppressed TSH.
- Metabolomic analyses reveal significant reductions in multiple lipid classes, with no changes in bone mineral density (BMD), indicating nuanced metabolic consequences of therapy.
- Introduction of liothyronine (L-T3) replacement raises concerns due to cardiac arrhythmia in one patient, emphasizing cautious titration and monitoring.
Study Background
Specialty calculators
For clinical reference; use professional judgment.
